EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.
LAB282 / LAB150 / LAB10x / Autobahn Labs / beLAB2122 / beLAB1407 / Danube Labs
| Programme | EVT201 |
| Therapeutic area/Indication | CNS - Insomnia (GABA-A) |
| Partner | JingXin |
| Status | Phase III |
| Programme | ND |
| Therapeutic area/Indication | Infectious Disease (Antibody) |
| Partner | SK bioscience |
| Status | Phase III |
| Programme | CT7001 |
| Therapeutic area/Indication | Oncology (CDK7) |
| Partner | Carrick |
| Status | Phase II |
| Programme | BAY2395840 |
| Therapeutic area/Indication | Diabetic Neuropathic Pain (BDKRB1) |
| Partner | Bayer |
| Status | Phase II |
| Programme | EVT401 |
| Therapeutic area/Indication | Immunology & Inflammation (P2X7) |
| Partner | CONBA Group |
| Status | Phase I |
| Programme | BAY2395840 |
| Therapeutic area/Indication | Gynaecology |
| Partner | Bayer |
| Status | Phase I |
| Programme | BAY2328065 |
| Therapeutic area/Indication | Gynaecology |
| Partner | Bayer |
| Status | Phase I |
| Programme | XP-105 |
| Therapeutic area/Indication | Oncology (mTORC1/2) |
| Partner | Xynomic Pharmaceuticals |
| Status | Phase I |
| Programme | TPM203 |
| Therapeutic area/Indication | Pemphigus Vulgaris (ND) |
| Partner | Topas Therapeutics |
| Status | Phase I |
| Programme | CNTX 6016 |
| Therapeutic area/Indication | Pain (CB2) |
| Partner | Centrexion |
| Status | Phase I |
| Programme | EVT894 |
| Therapeutic area/Indication | Chikungunya (ND) |
| Partner | Sanofi/NIH |
| Status | Phase I |
| Programme | EXS21546 |
| Therapeutic area/Indication | Oncology (A2a) |
| Partner | Exscientia |
| Status | Phase I |
| Programme | EVT801 |
| Therapeutic area/Indication | Oncology (VEGFR3) |
| Partner | Kazia Therapeutics |
| Status | Phase I |
| Programme | EVT8683 |
| Therapeutic area/Indication | Neurodegeneration (elF2b) |
| Partner | Bristol Myers Squibb |
| Status | Phase I |
| Programme | APN411 |
| Therapeutic area/Indication | Oncology - Immunotherapy (ND) |
| Partner | Sanofi/Apeiron |
| Status | Pre-clinical |
| Programme | QRB001 |
| Therapeutic area/Indication | Diabetes - beta cell replacement therapy |
| Partner | Currently unpartnered |
| Status | Pre-clinical |
| Programme | EVT075 |
| Therapeutic area/Indication | Covid-19/ HBV (ND) |
| Partner | Currently unpartnered |
| Status | Pre-clinical |
| Programme | GLPGxxx |
| Therapeutic area/Indication | Fibrosis (ND) |
| Partner | Galapagos |
| Status | Pre-clinical |
| Programme | BAYxxx |
| Therapeutic area/Indication | Nephrology (ND) |
| Partner | Bayer |
| Status | Pre-clinical |
| Programme | TPM501 |
| Therapeutic area/Indication | Celiac disease |
| Partner | Topas Therapeutics |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | CNS, Metabolic, Pain ...... |
| Partner | >10 further programmes |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | Nephrology |
| Partner | Bayer |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Immunology & Inflammation |
| Partner | UCB |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Neurodegeneration |
| Partner | Bristol Myers Squibb |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Oncology - solid tumours |
| Partner | Bristol Myers Squibb |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Immunology & Inflammation - Tissue Fibrosis |
| Partner | Pfizer |
| Status | Discovery |
| Programme | TargetPicV |
| Therapeutic area/Indication | Antiviral |
| Partner | Bayer/Haplogen |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Polycystic Ovary Syndrome |
| Partner | Bayer/Celmatix |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Nephrology |
| Partner | Novo Nordisk |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Nephrology |
| Partner | Chinook Therapeutics |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Various |
| Partner | Takeda |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Oncology |
| Partner | Breakpoint Therapeutics |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Anti-infectives |
| Partner | Forge Therapeutics |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | FSHD |
| Partner | Facio Therapies |
| Status | Discovery |
| Programme | INDY inhibitor |
| Therapeutic area/Indication | Metabolic |
| Partner | Eternygen |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Fibrotic disease |
| Partner | Fibrocor/Galapagos |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Gaucher |
| Partner | Centogene |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Various |
| Partner | Topas Therapeutics |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Heart failure |
| Partner | UKE |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Various |
| Partner | LAB282 / LAB150 / LAB10x / Autobahn Labs / beLAB2122 / beLAB1407 / Danube Labs |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Anti-infectives |
| Partner | >5 programmes |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives |
| Partner | >40 further programmes |
| Status | Discovery |
